Harmony Biosciences Holdings, Inc. (HRMY)
Automate Your Wheel Strategy on HRMY
With Tiblio's Option Bot, you can configure your own wheel strategy including HRMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HRMY
- Rev/Share 14.127
- Book/Share 14.284
- PB 2.4895
- Debt/Equity 0.2032
- CurrentRatio 3.7546
- ROIC 0.1808
- MktCap 2045304200.0
- FreeCF/Share 5.0781
- PFCF 6.889
- PE 11.1971
- Debt/Assets 0.1405
- DivYield 0
- ROE 0.2486
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 1
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | HRMY | Truist | -- | Buy | -- | $48 | July 21, 2025 |
| Resumed | HRMY | Goldman | -- | Neutral | -- | $33 | July 10, 2025 |
| Resumed | HRMY | Oppenheimer | -- | Outperform | -- | $61 | June 2, 2025 |
| Initiation | HRMY | Deutsche Bank | -- | Buy | -- | $55 | Feb. 11, 2025 |
| Initiation | HRMY | H.C. Wainwright | -- | Buy | -- | $75 | Dec. 17, 2024 |
| Resumed | HRMY | Raymond James | -- | Outperform | -- | -- | Oct. 10, 2024 |
| Initiation | HRMY | UBS | -- | Buy | -- | $56 | Sept. 10, 2024 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
Published: March 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY)Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Harmony and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Read More
Should Value Investors Buy Harmony Biosciences (HRMY) Stock?
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Harmony Biosciences (HRMY) Upgraded to Strong Buy: Here's Why
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Harmony Biosciences (HRMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder
Published: February 19, 2025 by: Benzinga
Sentiment: Negative
On Wednesday, Harmony Biosciences Holdings, Inc. HRMY received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH).
Read More
HRMY or ONC: Which Is the Better Value Stock Right Now?
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and BeiGene, Ltd. (ONC). But which of these two stocks is more attractive to value investors?
Read More
Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Harmony Biosciences (HRMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
About Harmony Biosciences Holdings, Inc. (HRMY)
- IPO Date 2020-08-19
- Website https://www.harmonybiosciences.com
- Industry Biotechnology
- CEO Jeffrey M. Dayno
- Employees 268